Now, genome sequencing and genome-scale metabolic models (GEMs) provide us with unprecedented detail about metabolic processes inside the cell. However, mostly due to computational complexity issues, the derived modelling approaches make surprisingly little use of thermodynamic concepts. Here, we review classical black-box models and modern approaches that integrate thermodynamics into GEMs. We also illustrate how the description of microbial growth as an energy converter can help to understand and quantify the trade-off between microbial growth rate and yield.The Chinese giant salamander, Andrias davidianus, is the largest amphibian species in the world; it is thus an economically and ecologically important species. The skin of A. davidianus exhibits complex adaptive structural and functional adaptations to facilitate survival in aquatic and terrestrial ecosystems. Here, we report the first full-length amphibian transcriptome from the dorsal skin of A. davidianus, which was assembled using hybrid sequencing and the PacBio and Illumina platforms. A total of 153,038 transcripts were hybrid assembled (mean length of 2039 bp and N50 of 2172 bp), and 133,794 were annotated in at least one database (nr, Swiss-Prot, KEGG, KOGs, GO, and nt). A total of 58,732, 68,742, and 115,876 transcripts were classified into 24 KOG categories, 1903 GO term categories, and 46 KEGG pathways (level 2), respectively. A total of 207,627 protein-coding regions, 785 transcription factors, 27,237 potential long non-coding RNAs, and 8299 simple sequence repeats were also identified. The hybrid-assembled transcriptome recovered more full-length transcripts, had a higher N50 contig length, and a higher annotation rate of unique genes compared with that assembled in previous studies using next-generation sequencing. The high-quality full-length reference gene set generated in this study will help elucidate the genetic characteristics of A. davidianus skin and aid the identification of functional skin proteins.Epigenetic dysregulation has long been identified as a key driver of leukemogenesis in acute myeloid leukemia (AML). However, epigenetic drugs such as histone deacetylase inhibitors (HDACi) targeting epigenetic alterations in AML have obtained only limited clinical efficiency without clear mechanism. Fortunately, we screened out a novel epigenetic agent named Apigenin-Vorinostat-Conjugate (AVC), which provides us a possibility to handle the heterogenous malignancy. Its inhibition on HDACs was presented by HDACs expression, enzyme activity, and histone acetylation level. Its efficacy against AML was detected by cell viability assay and tumor progression of AML mouse model. Apoptosis is the major way causing cell death. We found AVC efficiently suppresses leukemogenesis whereas sparing the normal human cells. Kasumi-1 cells are at least twenty-fold higher sensitive to AVC (IC50=0.024μM) than vorinostat (IC50=0.513μM) and Ara-C (IC50=0.4366μM). Furthermore, it can efficiently regress the tumorigenesis in AML mouse model while keeping the pivotal organs safe, demonstrating a feasibility and favorable safety profile in treatment of AML. Collectively, these pre-clinical data suggest a promising potential utilizing flavonoid-HDACi-conjugate as a next-generation epigenetic drug for clinical therapy against AML.Periorbital deformities can be corrected using hyaluronic acid (HA) injections. However, previous studies have not evaluated the effect of using different injection techniques (eg, a needle versus cannula) on efficacy and safety.
To investigate the efficacy and safety of HA for the correction of periorbital deformities, when using either needle or cannula-assisted injections.
This was a prospective, randomized-controlled (with crossover), evaluator blinded study. Forty-two subjects were recruited, with a mean age of 44.82 ± 11.62 years. Subjects underwent two treatment sessions, spaced two weeks apart and attended one follow up visit at Week 4, following the last treatment. Subjects were randomized in a 331 ratio, whereby 18 subjects received injections by needle, 18 received injections by cannula and 6 were randomized to act as their own control at Baseline. Those in the control group were randomized (n = 3) to needle or cannula injections at Week 4 and proceeded with the same visit schedule as those treated at Baseline. At Weeks 2 and 4 post-treatment, subject satisfaction was evaluated and information on adverse effects (AEs) was collected. A blinded reviewer assessed subject imagery using standardized efficacy scales.
Chi-square tests did not reveal any associations between treatment group and efficacy, safety, nor subject satisfaction scores (p &gt; = 0.05). https://www.selleckchem.com/products/trometamol.html AEs reported in subject diaries were mild-to-moderate in nature and expected.
For the treatment of infraorbital deformities, hyaluronic acid injections performed using either a cannula or needle result in similarly high efficacy and safety ratios.
For the treatment of infraorbital deformities, hyaluronic acid injections performed using either a cannula or needle result in similarly high efficacy and safety ratios.Breast cancer is the main lethal disease among females. The combination of lobaplatin and microwave hyperthermia plays a crucial role in several kinds of cancer in the clinic, but it's possible mechanism in breast cancer has remained indistinct.MethodsMouse models were used to detect breast cancer progression. Cell growth was explored with MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulphonyl)-2H-tetrazolium) and colony formation assays. Cell migration and invasion were investigated with a transwell assay. Cell apoptosis was probed with flow cytometry. The expression of apoptosis-associated proteins was examined with Western blots.ResultCombination treatment decreased breast cancer cell viability, colony formation, cell invasion and metastasis. In addition, the treatment induced breast cancer cell apoptosis and autophagy, activated the JNK signaling pathway, suppressed the AKT/mTOR signaling pathway, and downregulated IAP and Bcl-2 family protein expression.ConclusionThese results indicate that lobaplatin is an effective breast cancer antitumor agent.